Walgreens November Sales Decrease 3.9 Percent

  Walgreens November Sales Decrease 3.9 Percent

Business Wire

DEERFIELD, Ill. -- December 05, 2012

Walgreens (NYSE: WAG) (Nasdaq: WAG) had November sales of $5.85 billion, a
decrease of 3.9 percent from $6.09 billion for the same month in fiscal 2012.

Total front-end sales decreased 0.3 percent compared with the same month in
fiscal 2012, while comparable store front-end sales decreased 1.7 percent.
Customer traffic in comparable stores decreased 4.9 percent while basket size
increased 3.2 percent.

Prescriptions filled at comparable stores decreased by 2.9 percent in November
and by a day-fall adjusted (DFA) 2.6 percent. This year’s November had one
additional Thursday and Friday and one fewer Tuesday and Wednesday compared
with November 2011, negatively impacting prescriptions filled in comparable
stores by 0.3 percentage point. DFA prescriptions filled at comparable stores
were positively impacted by 0.2 percentage point due to the higher incidence
of flu in this year’s November.

Click here for a graph showing the trend of comparable prescriptions filled
adjusted for day fall and flu impacts.

November pharmacy sales decreased 4.7 percent, while comparable store pharmacy
sales decreased 8.8 percent. Calendar day shifts negatively impacted pharmacy
sales in comparable stores by 0.3 percentage point. DFA comparable store
pharmacy sales were negatively impacted by 9.0 percentage points due to
generic drug introductions in the last 12 months. Pharmacy sales accounted for
63.2 percent of total sales for the month.

Flu shots administered at pharmacies and clinics season-to-date were nearly
4.6 million versus approximately 5 million last year.

Sales in comparable stores decreased by 6.2 percent in November. Calendar day
shifts negatively impacted total comparable sales by 0.2 percentage point,
while generic drug introductions in the last 12 months negatively impacted
total comparable sales by 5.7 percentage points.

Registrations for Walgreens Balance™ Rewards loyalty program, which launched
in September, totaled more than 38 million through November.

Calendar year-to-date sales were $63.82 billion, a decrease of 3.6 percent
from $66.20 billion in 2011.

Total sales for the first quarter of fiscal 2013, which ended Nov. 30, were
$17.34 billion, down 4.5 percent from $18.16 billion in the first quarter of
fiscal 2012. Comparable store sales for the first quarter of fiscal 2013
decreased 7.7 percent, while front-end comparable store sales for the quarter
decreased 2.0 percent. Prescriptions filled at comparable stores decreased 4.6
percent and total prescriptions decreased 3.0 percent in the first quarter.
Comparable pharmacy sales for the first quarter decreased 10.8 percent.

Walgreens opened 39 stores during November, including 10 relocations and
closed one.

At Nov. 30, Walgreens operated 8,516 locations in all 50 states, the District
of Columbia, Puerto Rico and Guam. That includes 8,057 drugstores, 246 more
than a year ago, including 107  net stores acquired over the last 12 months.
The company also operates infusion and respiratory services facilities,
specialty pharmacies and mail service facilities. Its Take Care Health Systems
subsidiary manages more than 700 in-store convenient care clinics and worksite
health and wellness centers.

         
                  November Comparable Sales and Prescriptions Filled
                                                 
                                                     Cough,     Flu
                           Calendar       Generics   Cold, Flu   Shot
                  Actual   Shift Impact   Impact     Impact      Impact
                                                                 
Total Comp Sales  -6.2%    -0.2%          -5.7%      -0.1%       0.0%
                                                                 
Comp Front End    -1.7%    -              -          -           -
                                                                 
Comp Rx Sales     -8.8%    -0.3%          -9.0%      -0.1%       0.0%
                                                                 
Comp Rx Scripts   -2.9%*   -0.3%          -          0.2%        0.1%

* Includes +2.9 percentage points from patients filling more 90-day
prescriptions

Please note: Sales numbers and the adjustments shown in the table are
preliminary, unaudited and subject to revision. Comparable stores are defined
as those drugstore locations open for at least 12 consecutive months without
closure for seven or more consecutive days and without a major remodel or a
natural disaster in the past 12 months. Acquired operating locations and
relocations are not included as comparable stores for the first 12 months
after the acquisition or relocation.

Cautionary Note Regarding Forward-Looking Statements: Statements in this
release that are not historical are forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as "expect," “likely,” "outlook," “forecast, "would,"
"could," "should," “can,” “will,” "project," "intend," "plan," "goal,”
“continue," "sustain," “synergy,” "on track," "believe," "seek," "estimate,"
"anticipate," "may," “possible,” "assume," and variations of such words and
similar expressions are intended to identify such forward-looking statements.
These forward-looking statements are not guarantees of future performance and
involve risks, assumptions and uncertainties, including, but not limited to,
those described in Item 1A (Risk Factors) of our most recent Annual Report on
Form 10-K, which is incorporated herein by reference, and in other documents
that we file or furnish with the Securities and Exchange Commission. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those
indicated or anticipated by such forward-looking statements. Accordingly, you
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date they are made. Except to the extent required
by law, Walgreens does not undertake, and expressly disclaims, any duty or
obligation to update publicly any forward-looking statement after the date of
this report, whether as a result of new information, future events, changes in
assumptions or otherwise.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20121205005457/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50498118&lang=en

Contact:

Walgreens
Media Contact:
Robert Elfinger, 847-315-2962
or
Investor Contacts:
Rick Hans, CFA, 847-315-2385
Snehal Shah, 847-315-2361
http://news.walgreens.com
 
Press spacebar to pause and continue. Press esc to stop.